in vivo News and Research

RSS

Beyond food: Bran-based gels show potential for targeted drug delivery

When it comes to colon health, the benefits of wheat and rye bran in wholegrain foods are well-known. Now researchers in Sweden have shown how these fibers may have a therapeutic use, too.

12 Nov 2026

Mogrify to present preclinical proof-of-concept data for first-in-class retinal in vivo reprogramming therapy

Mogrify Limited (Mogrify®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies, today announced it will present preclinical proof-of-concept data at FLORetina-ICOOR 2026.

From Mogrify 11 Nov 2026

Towards a new approach to treating chronic blood disorders

A previously unrecognised weakness in the immune defenses against certain blood neoplasms could offer a promising target for future treatments.

6 Nov 2026

Anti-PEG antibodies drive contrasting liposome skin toxicity across species

This new article publication from Acta Pharmaceutica Sinica B discusses how anti-polyethylene glycol antibodies affect the movement of stealth liposomes from blood into skin, revealing contrasting distribution and toxicity patterns in mice and rats.

5 Nov 2026

Elusive HIV strains cause breakthrough infections after antibody treatment ends

The broadly neutralizing antibody VRC01 has been thoroughly vetted as a potential prophylactic that could prevent people from becoming infected with HIV.

5 Nov 2026

Scientists develop slug-inspired hydrogel to seal gastrointestinal fistulas

Gastrointestinal fistulas are abnormal passages between the digestive tract and another organ or tissue. They are a common complication of surgery, trauma, inflammatory diseases, and malignant tumors and can be life-threatening in severe cases.

5 Nov 2026

Researchers develop method to generate billions of cDC1 immune cells

Conventional type 1 dendritic cells, known as cDC1 cells, are immune cells that help initiate responses against intracellular pathogens and tumors.

4 Nov 2026

Gene therapy successfully corrects genetic defect in alpha-1 antitrypsin deficiency

In a landmark achievement in the field of genetic medicine, researchers have reported the very first published case in a peer-reviewed journal of a successful clinical treatment of a patient with alpha-1 antitrypsin deficiency (PiZZ) using in vivo gene therapy.

2 Nov 2026

Mechanical force triggers metabolic changes that promote orthodontic bone formation

Bone adapts to mechanical force through coupled formation and resorption, a principle central to orthodontics.

30 Oct 2026

Researchers uncover molecular pathway controlling bone resorption and tooth eruption

RUNX2 is best known as a master transcription factor of osteoblast differentiation. Mutations in, or haploinsufficiency of RUNX2 cause CCD, a skeletal disorder characterized by delayed permanent tooth eruption, supernumerary teeth and clavicular defects.

30 Oct 2026

Light-activated molecular cages offer precise control over protein degradation

Researchers have created a molecular "cage" that keeps protein-degrading drug molecules inactive until they are exposed to low-energy red light.

30 Oct 2026

Study reveals immune rheostat maintaining skin barrier homeostasis

As the steadfast protector of the body's interior, the skin must be able to swiftly respond to stressors from the outside world and then return to a steady state in order to maintain everyday operations. Coordinating that agile response are epidermal stem cells, which produce the overlying protective layers of specialized skin cells sent to the surface while also maintaining a ready pool of new stem cells to draw from.

30 Oct 2026

Newly discovered protein helps preserve egg chromosome integrity during aging

Eggs follow a very different developmental path from sperm. Once a male hits puberty, sperm cells are produced continuously throughout his life.

29 Oct 2026

New host target identified to block hepatitis E virus

Hepatitis E virus (HEV) is a major cause of acute viral hepatitis, yet antiviral treatment remains largely limited to the off-label use of ribavirin. Ribavirin can cause substantial toxicity, is contraindicated during pregnancy and does not reliably benefit every patient.

29 Oct 2026

DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterized by extremely fragile skin and progressive, debilitating complications.

28 Oct 2026

Researchers harness cancer cells' carbon monoxide to produce anticancer drug

What if we could use a cancer's own byproduct to make drugs that destroy tumor cells from the inside? That is exactly what Katsunori Tanaka and his team have done at the RIKEN Pioneering Research Institute (PRI) in Japan.

23 Oct 2026

Glucose priming may improve tumor targeting for chemotherapy nanocarriers

Chemotherapy selectivity is limited by systemic toxicity. pH‑sensitive nanocarriers exploit tumor acidity as a release trigger but respond passively to a modest, heterogeneous gradient.

21 Oct 2026

ScionxBio announces collaboration to develop long-acting xRNA therapeutics

ScionxBio (the "company", operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio's proprietary TERA® platform.

From ScionxBio 21 Oct 2026

AI study of 101,000 patients links brown fat to heart and mental health

In a retrospective analysis of PET-CT records from 101,243 patients, researchers found that detectable brown fat was associated with lower prevalence of cardiometabolic and psychiatric conditions, while greater activity, particularly in the axillary region, was linked to more favourable metabolic outcomes. Medication screening identified losartan, which increased brown fat thermogenic activity in laboratory experiments and energy expenditure in mice, although its effects on human brown fat remain unproven.

15 Oct 2026

Does the type of hand sanitizer matter? A study involving 568 people suggests it might

In a 72-day randomized trial involving 568 participants in Japan, an experimental hand sanitizer containing ethanol, benzalkonium chloride, and lactic acid was associated with a 40% lower cumulative incidence of upper respiratory symptoms than a commercial ethanol-based sanitizer. Participants using the experimental formulation also experienced fewer illness-related work restrictions, although infections were not laboratory-confirmed and the proposed residual antimicrobial mechanism was not directly tested.

14 Oct 2026